论文部分内容阅读
表皮生长因子受体(EGFR)为肿瘤治疗的重要靶点,EGFR抑制剂可以通过促进细胞凋亡、细胞周期重分布、降低辐射抗性、抑制血管形成、减少放射损伤修复和减少肿瘤细胞再增殖等机制起到放射增敏的效果。靶向治疗联合放疗可能是靶向治疗向前发展的重要途径,也是放射治疗提高自身疗效的良好契机。尽管还有诸多问题尚待解决,但随着基础研究的不断深入,EGFR抑制剂联合放疗会迎来更广阔的临床应用前景。
Epidermal growth factor receptor (EGFR) is an important target for tumor therapy. EGFR inhibitors can protect the tumor cells by promoting apoptosis, cell cycle redistribution, reducing radiation resistance, inhibiting blood vessel formation, reducing radiation damage and reducing tumor cell proliferation And other mechanisms play a radiosensitization effect. Targeted therapy combined with radiotherapy may be targeted therapy forward an important way forward, but also to improve the efficacy of radiation therapy a good opportunity. Although there are still many problems to be solved, with the deepening of basic research, EGFR inhibitors combined with radiotherapy will usher in a broader clinical application.